×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Protalix BioTherapeutics Inc.. (PLX) NYSE MKT LLC

$1.26 0.01 (0.80%)

Market Cap: $92.05M

As of 03/28/24 04:00 PM EDT. Market closed.

(PLX)

Protalix BioTherapeutics Inc.. (PLX)
NYSE MKT LLC

$1.26
0.01 (0.80%)

Market Cap: $92.05M

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic ... read more

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa?galactosidase read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Dror Bashan
Full Time Employees
266
URL
Address
Karmiel, 2 Snunit St Science Park Pob 455, 2161401.
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Dror Bashan
Full Time Employees
266
Address
Karmiel, 2 Snunit St Science Park Pob 455, 2161401.
PRICE CHART FOR PROTALIX BIOTHERAPEUTICS INC.
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.26
Previous Close
$1.25
Days Range
$1.24 - $1.28
52 week range
$1.21 - $3.55
Volume
282,403
Avg. Volume (30 days)
421,953
Market Cap
$92.05M
Dividend Yield
-
P/E
11.07
Shares Outstanding
73,052,124
Open
$1.26
Previous Close
$1.25
Days Range
$1.24 - $1.28
52 week range
$1.21 - $3.55
Volume
282,403
Avg. Volume (30 days)
421,953
Market Cap
$92.05M
Dividend Yield
-
P/E
11.07
Shares Outstanding
73,052,124
FINANCIAL STATEMENTS FOR PROTALIX BIOTHERAPEUTICS INC.
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR PROTALIX BIOTHERAPEUTICS INC.
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Bashan DrorPRESIDENT AND CEOOct 19, 2023 Buy$1.4064,51690,484132,516Oct 20, 2023, 06:50 AM
Schwartz AharonDirectorJan 03, 2023 Buy$1.42110,000155,815174,000Jan 05, 2023, 05:08 PM
Bashan DrorPresident and CEOApr 11, 2022 Buy$1.5068,000102,00068,000Apr 13, 2022, 04:05 PM
Dexcel Pharma Technologies Ltd.10% OwnerJun 03, 2021 Sale$2.25857,5061,932,3043,637,314Jun 03, 2021, 05:40 PM
Dexcel Pharma Technologies Ltd.10% OwnerJun 02, 2021 Sale$2.5661,211156,5534,494,820Jun 03, 2021, 05:40 PM
Schwartz AharonDirectorApr 07, 2020 Buy$2.4364,000155,26464,000Apr 13, 2020, 04:05 PM
Manor MoshePresident & CEOMay 16, 2017 Buy$0.8150,00040,50050,000May 16, 2017, 09:31 AM
Camber Capital Management LLC10% OwnerDec 02, 2016 Sale$0.322,500,000792,00010,775,000Dec 06, 2016, 03:26 PM
Shaaltiel YosephExecutive VP, R&DSep 15, 2016 Option Exercise$0.00122,162122585,916Sep 16, 2016, 05:01 PM
Maimon YossiVice President & CFODec 14, 2015 Buy$0.7810,0007,80010,000Dec 15, 2015, 07:30 AM
Camber Capital Management LLC10% OwnerOct 19, 2015 Buy$1.004,000,4234,000,43613,275,000Oct 20, 2015, 02:18 PM
Bronfeld ZeevDirectorAug 13, 2014 Sale$2.474,400,00010,868,00010,066,319Aug 15, 2014, 04:30 PM
Bio-Cell Ltd10% OwnerAug 13, 2014 Sale$2.474,400,00010,868,00010,066,319Aug 15, 2014, 04:30 PM
Akirov AlfredDirectorAug 15, 2013 Sale$5.072,33011,8134,915,383Aug 16, 2013, 06:00 PM
Akirov AlfredDirectorAug 14, 2013 Sale$5.05110,000555,7504,927,713Aug 16, 2013, 06:00 PM
Akirov AlfredDirectorMar 12, 2013 Sale$5.7010,00057,0005,027,713Mar 14, 2013, 07:00 PM
Akirov AlfredDirectorMar 11, 2013 Sale$5.7218,300104,7375,055,713Mar 12, 2013, 06:30 PM
Akirov AlfredDirectorMar 08, 2013 Sale$5.8616,89899,0685,062,911Mar 12, 2013, 06:30 PM
Akirov AlfredDirectorMar 06, 2013 Sale$5.694,70026,7375,084,046Mar 08, 2013, 05:04 PM
Akirov AlfredDirectorMar 07, 2013 Sale$5.728,43548,2335,076,346Mar 08, 2013, 05:04 PM
Shaaltiel YosephExecutive VP, R&DMay 02, 2012 Sale$7.13300,0002,139,000463,754May 04, 2012, 05:14 PM
Maimon YossiVP, Chief Financial OfficerMay 02, 2012 Option Exercise$1.64125,964206,337125,964May 04, 2012, 05:13 PM
Maimon YossiVP, Chief Financial OfficerMay 02, 2012 Sale$7.13125,964898,1230May 04, 2012, 05:13 PM
Aviezer DavidPresident & CEOMay 02, 2012 Option Exercise$0.35450,000159,421450,000May 04, 2012, 05:11 PM
Aviezer DavidPresident & CEOMay 02, 2012 Sale$7.13450,0003,208,5000May 04, 2012, 05:11 PM
Almon Einat BrillSVP, Product DevelopmentMay 02, 2012 Option Exercise$1.47166,848246,076166,848May 04, 2012, 05:10 PM
Almon Einat BrillSVP, Product DevelopmentMay 02, 2012 Sale$7.13166,8481,189,6260May 04, 2012, 05:10 PM
Maimon YossiVP, Chief Financial OfficerOct 07, 2010 Option Exercise$9.737,76975,5920Oct 08, 2010, 04:10 PM
Maimon YossiVP, Chief Financial OfficerOct 07, 2010 Option Exercise$0.9777,76975,5910Oct 08, 2010, 04:10 PM
Maimon YossiVP, Chief Financial OfficerOct 07, 2010 Sale$9.6770,000676,9000Oct 08, 2010, 04:10 PM
Almon Einat BrillVP, Product DevelopmentOct 06, 2010 Option Exercise$0.9770,00068,0400Oct 06, 2010, 08:21 PM
Almon Einat BrillVP, Product DevelopmentOct 05, 2010 Sale$9.0820,000181,6000Oct 06, 2010, 08:21 PM
Almon Einat BrillVP, Product DevelopmentOct 04, 2010 Sale$9.0235,000315,7000Oct 06, 2010, 08:21 PM
Almon Einat BrillVP, Product DevelopmentOct 06, 2010 Sale$9.2915,000139,3500Oct 06, 2010, 08:21 PM
Maimon YossiVP, Chief Financial OfficerSep 07, 2010 Option Exercise$0.9770,00068,0400Sep 08, 2010, 04:34 PM
Maimon YossiVP, Chief Financial OfficerSep 07, 2010 Sale$8.1631,500257,0400Sep 08, 2010, 04:34 PM
Maimon YossiVP, Chief Financial OfficerSep 03, 2010 Sale$8.0038,500308,0000Sep 08, 2010, 04:34 PM
Almon Einat BrillVP, Product DevelopmentSep 07, 2010 Option Exercise$0.9250,00045,8840Sep 08, 2010, 04:30 PM
Almon Einat BrillVP, Product DevelopmentSep 07, 2010 Sale$8.1622,500183,6000Sep 08, 2010, 04:30 PM
Almon Einat BrillVP, Product DevelopmentSep 03, 2010 Sale$8.0027,500220,0000Sep 08, 2010, 04:30 PM
Shaaltiel YosephExecutive VP, R&DAug 06, 2010 Sale$7.004,61932,333763,754Aug 09, 2010, 05:00 PM
Shaaltiel YosephExecutive VP, R&DAug 05, 2010 Sale$7.0048,408338,856768,373Aug 09, 2010, 05:00 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Bashan DrorPRESIDENT AND CEO10/19/202390,484
Schwartz AharonDirector01/03/2023155,815
Bashan DrorPresident and CEO04/11/2022102,000
Dexcel Pharma Technologies Ltd.10% Owner06/03/20211,932,304
Dexcel Pharma Technologies Ltd.10% Owner06/02/2021156,553
Schwartz AharonDirector04/07/2020155,264
Manor MoshePresident & CEO05/16/201740,500
Camber Capital Management LLC10% Owner12/02/2016792,000
Shaaltiel YosephExecutive VP, R&D09/15/2016122
Maimon YossiVice President & CFO12/14/20157,800
Camber Capital Management LLC10% Owner10/19/20154,000,436
Bronfeld ZeevDirector08/13/201410,868,000
Bio-Cell Ltd10% Owner08/13/201410,868,000
Akirov AlfredDirector08/15/201311,813
Akirov AlfredDirector08/14/2013555,750
Akirov AlfredDirector03/12/201357,000
Akirov AlfredDirector03/11/2013104,737
Akirov AlfredDirector03/08/201399,068
Akirov AlfredDirector03/06/201326,737
Akirov AlfredDirector03/07/201348,233
Shaaltiel YosephExecutive VP, R&D05/02/20122,139,000
Maimon YossiVP, Chief Financial Officer05/02/2012206,337
Maimon YossiVP, Chief Financial Officer05/02/2012898,123
Aviezer DavidPresident & CEO05/02/2012159,421
Aviezer DavidPresident & CEO05/02/20123,208,500
Almon Einat BrillSVP, Product Development05/02/2012246,076
Almon Einat BrillSVP, Product Development05/02/20121,189,626
Maimon YossiVP, Chief Financial Officer10/07/201075,592
Maimon YossiVP, Chief Financial Officer10/07/201075,591
Maimon YossiVP, Chief Financial Officer10/07/2010676,900
Almon Einat BrillVP, Product Development10/06/201068,040
Almon Einat BrillVP, Product Development10/05/2010181,600
Almon Einat BrillVP, Product Development10/04/2010315,700
Almon Einat BrillVP, Product Development10/06/2010139,350
Maimon YossiVP, Chief Financial Officer09/07/201068,040
Maimon YossiVP, Chief Financial Officer09/07/2010257,040
Maimon YossiVP, Chief Financial Officer09/03/2010308,000
Almon Einat BrillVP, Product Development09/07/201045,884
Almon Einat BrillVP, Product Development09/07/2010183,600
Almon Einat BrillVP, Product Development09/03/2010220,000
Shaaltiel YosephExecutive VP, R&D08/06/201032,333
Shaaltiel YosephExecutive VP, R&D08/05/2010338,856
Load More Insider Transactions
FUNDS WITH A POSITION IN PROTALIX BIOTHERAPEUTICS INC.
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.3,457,7340.00016%8.89%Other
GEODE CAPITAL MANAGEMENT, LLC724,5750.00013%3.48%Other
RENAISSANCE TECHNOLOGIES LLC665,6000.00183%7.16%Other
SCULPTOR CAPITAL LP37,000 (Put)0.00139%No changeEvent Driven
SCULPTOR CAPITAL LP37,0000.00139%No changeEvent Driven
CHANGE IN SHARES OUTSTANDING FOR PROTALIX BIOTHERAPEUTICS INC.
STOCK BUYBACKS FOR PROTALIX BIOTHERAPEUTICS INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
3.33%
1Q
12/31/2023
06/30/2023
4.06%
2Q
12/31/2023
09/30/2022
74.91%
5Q
12/31/2023
06/30/2022
82.93%
6Q
12/31/2023
03/31/2022
88.85%
7Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
3.33%
1Q
06/30/2023
4.06%
2Q
09/30/2022
74.91%
5Q
06/30/2022
82.93%
6Q
03/31/2022
88.85%
7Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR PROTALIX BIOTHERAPEUTICS INC.
LOADING...